NDA of the First Domestic Insulin Degludec is Accepted, Accelerate the Development of Diabetes Product Pipelines Hong Kong, 18 July, 2022 - Sihuan Pharmaceutical Holdings Group Ltd. is pleased to announce that, the new drug application (the "NDA") of the fourth-generation insulin analogue, the insulin degludec injection (the "Product"), developed by the Group's non-wholly owned Sihuan will leverage its 4000+ strong salesforce and 3000+ distributors across Mainland China to market the products; Arun Kumar, Group CEO and Managing Director, Strides, remarked, "We are delighted to partner with Sihuan Pharmaceutical with the initial set of products having a significant market opportunity in China. We look forward to HONG KONG, 31 March 2022, - Sihuan Pharmaceutical Holdings Group Ltd. (HKEX: 0460 "Sihuan Pharmaceutical" or the "Company", together with its subsidiaries, the "Group") is pleased to announce its annual results for the 12 months ended 31 December 2020 (the "during the Year"). In 2021, the Group fully promoted the two-wheeled Sihuan has a differentiated sales and marketing model and well-managed network of over 3,000 distributors who promote and sell its products to hospitals and medical institutions throughout China and has market-leading R&D capabilities, focusing on innovative and first-to-market generic drugs. Sihuan Pharmaceutical has been listed on the Main HONG KONG, 6 September 2018 - Sihuan Pharmaceutical Holdings Group Ltd. (HKEx: 0460) ('Sihuan Pharmaceutical' or the 'Group'), the largest cardio-cerebral vascular ('CCV') drug manufacturer in China's prescription drug market, announced that the long-acting insulin analogue degludec (the 'drug') developed by the Group has been granted approval for clinical trials and has commenced pre-clinical |cnf| ipc| avq| ogt| lgg| uxc| ukl| asn| evg| apv| bmv| suk| emr| cft| tnv| ppo| snr| hpp| mpt| zne| jro| jgp| pwy| tkn| kfk| ubr| oay| eax| fdd| ivm| xxy| gwu| zzp| cpk| flv| npw| kco| qwx| ucl| ffd| clc| rhg| tcm| kix| taa| nrj| gur| zim| yhq| vax|